IART icon

Integra LifeSciences

15.06 USD
-0.41
2.65%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
15.06
0.00
0%
1 day
-2.65%
5 days
-5.93%
1 month
9.37%
3 months
18.68%
6 months
-32.28%
Year to date
-34.58%
1 year
-14.67%
5 years
-66.76%
10 years
-52.46%
 

About: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Employees: 4,396

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

16% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 64

1.18% less ownership

Funds ownership: 95.24% [Q1] → 94.06% (-1.18%) [Q2]

6% less funds holding

Funds holding: 218 [Q1] → 206 (-12) [Q2]

18% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 44

45% less capital invested

Capital invested by funds: $1.62B [Q1] → $897M (-$721M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

Financial journalist opinion

Based on 3 articles about IART published over the past 30 days

Positive
Seeking Alpha
3 days ago
Integra LifeSciences Still Recovering From Self-Inflicted Wounds
Integra LifeSciences remains deeply discounted due to ongoing operational setbacks, with the market adopting a cautious 'show me' stance until clear improvements emerge. Remediation and margin improvement plans are underway, but shipping holds and tariffs continue to pressure revenue and profitability, delaying a full recovery until at least 2026. Core businesses, including higher-value wound care products, have shown resilience, and long-term growth drivers remain intact, supporting potential upside for patient investors.
Integra LifeSciences Still Recovering From Self-Inflicted Wounds
Neutral
Seeking Alpha
3 days ago
Integra LifeSciences Holdings Corporation (IART) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Good morning, everyone, and welcome to Day 3 of the Morgan Stanley Global Healthcare Conference. Thanks so much, everyone, for joining.
Integra LifeSciences Holdings Corporation (IART) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
15 days ago
Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at two upcoming investor healthcare conferences:
Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences
Neutral
Seeking Alpha
1 month ago
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Christopher Ward – Senior Director of Investor Relations Lea Daniels Knight – Executive VP & CFO Mojdeh Poul – President, CEO & Director Analysts Lilia-Celine Breton Lozada - JPMorgan Chase & Co, Research Division Ravi Misra - Truist Securities, Inc., Research Division Unknown Analyst Vikramjeet Singh Chopra - Wells Fargo Securities, LLC, Research Division Xuyang Li - Jefferies LLC, Research Division Operator Good day, and thank you for standing by. Welcome to the Integra LifeSciences Second Quarter 2025 Financial Results Call.
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Neutral
The Motley Fool
1 month ago
Integra (IART) Q2 Revenue Beats by 5%
Integra (IART) Q2 Revenue Beats by 5%
Integra (IART) Q2 Revenue Beats by 5%
Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
1 month ago
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences Reports Second Quarter 2025 Financial Results
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025.
Integra LifeSciences Reports Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
2 months ago
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025
Positive
Zacks Investment Research
2 months ago
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Charts implemented using Lightweight Charts™